Eli Lilly Partners with Ascidian Therapeutics in $1.9 Billion RNA Exon Editing Deal for Kidney Diseases
核心洞察
Eli Lilly and Ascidian Therapeutics (搜索) have entered a $1.9 billion global research collaboration to develop RNA exon editing (搜索) therapies for monogenic kidney diseases (搜索).
Ascidian's platform can rewrite RNA at the exon level without modifying DNA, addressing large genes with high mutational variance that conventional gene editing tools cannot target.
Over 60 genetic diseases affect the kidneys, with upwards of 3.5 million Americans living with severe inherited kidney disease (搜索), yet no disease-modifying treatments exist for most conditions.
Eli Lilly has entered a global research collaboration and licensing agreement with Ascidian Therapeutics (搜索) worth up to $1.9 billion to discover and develop therapies for monogenic kidney diseases (搜索) using RNA exon editing (搜索) technology. The partnership represents a significant investment in addressing inherited diseases that have remained largely out of reach for existing therapeutic technologies.
Revolutionary RNA Exon Editing Platform
Ascidian's platform is built around the ability to rewrite RNA at the exon level, editing multiple whole exons at the kilobase scale to repair faulty genetic instructions that drive disease. The technology uses the cell's natural RNA splicing machinery to make corrections without modifying the underlying genome or introducing foreign enzymes.
According to Ascidian, the approach is designed to deliver the durability associated with gene therapy while substantially reducing the risks that come with direct DNA editing or gene replacement strategies. The company's drugs are DNA constructs that, after being delivered into the body via a viral vector or lipid nanoparticle system, are transcribed into mutation-free, exon-only RNA in the body, allowing healthy protein to be transcribed.
Addressing Unmet Medical Need in Kidney Disease
The distinction is particularly meaningful in kidney disease, where many of the causative genes are large or exhibit high mutational variance, characteristics that have historically made them poor candidates for conventional gene editing tools. Ascidian's exon editors were specifically developed to address those limitations.
The unmet need in monogenic kidney disease is substantial. Over 60 genetic diseases are known to affect the kidneys, and upwards of 3.5 million Americans currently live with severe inherited kidney disease (搜索). Many of these conditions progress to kidney failure (搜索), requiring dialysis or transplant, yet no disease-modifying treatments exist for the majority of them.
"RNA exon editing (搜索) gives us the ability to rewrite genes at their source, without altering DNA, opening the door to diseases long out of reach," said Michael Ehlers, MD, PhD, president and CEO of Ascidian Therapeutics (搜索). "Combined with Lilly's genetic medicine expertise, we aim to dramatically reduce the burden of genetic kidney disease."
Partnership Structure and Financial Terms
Under the terms of the agreement, Eli Lilly receives exclusive, target-specific rights to Ascidian's RNA exon editing (搜索) technology for undisclosed kidney disease targets, while Ascidian will lead discovery and selected preclinical activities. Eli Lilly will assume responsibility for additional preclinical work, clinical development, manufacturing, and commercialization.
Ascidian is eligible to receive up to $1.9 billion, including an upfront payment, development and commercial milestone payments, and tiered royalties on global sales. The company will also retain the right to independently pursue other kidney targets or partner with additional companies outside the scope of this agreement.
Strategic Expansion in Genetic Medicine
The collaboration with Ascidian reflects a broader industry shift toward RNA-based approaches as an alternative to permanent DNA modification. Lilly has been expanding its presence in genetic medicines, and the option to expand the collaboration to additional targets beyond the initial kidney focus suggests both companies see this as a platform partnership with potential well beyond a single disease area.
"Lilly and Ascidian believe that patients with serious monogenic kidney diseases (搜索) deserve effective treatment options and that an RNA-based approach is a compelling strategy for those diseases," Ehlers added.
The deal represents one of three major licensing agreements announced by Lilly this week, demonstrating the company's aggressive expansion strategy funded by rapidly growing revenues from its GLP-1-based weight-loss and diabetes medicines.